[go: up one dir, main page]

WO2008067288A3 - Procédés permettant d'inhiber la réaction à corps étranger face à des matériaux implantés - Google Patents

Procédés permettant d'inhiber la réaction à corps étranger face à des matériaux implantés Download PDF

Info

Publication number
WO2008067288A3
WO2008067288A3 PCT/US2007/085598 US2007085598W WO2008067288A3 WO 2008067288 A3 WO2008067288 A3 WO 2008067288A3 US 2007085598 W US2007085598 W US 2007085598W WO 2008067288 A3 WO2008067288 A3 WO 2008067288A3
Authority
WO
WIPO (PCT)
Prior art keywords
foreign body
inhibitors
gtpase activity
methods
rho
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/085598
Other languages
English (en)
Other versions
WO2008067288A2 (fr
Inventor
Themis R Kyriades
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of WO2008067288A2 publication Critical patent/WO2008067288A2/fr
Publication of WO2008067288A3 publication Critical patent/WO2008067288A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des procédés et des compositions qui permettent d'inhiber la réponse à corps étranger face à des matériaux implantés. Les procédés consistent à inhiber la formation de cellules géantes à corps étranger en administrant une quantité efficace d'un antagoniste de l'activité GTPasique de la Rho. Dans un mode de réalisation préféré, les procédés consistent à mettre en contact un matériau implanté ou le tissu ou les liquides corporels adjacents avec une quantité efficace d'un antagoniste de l'activité GTPasique de la Rho afin d'empêcher la formation de cellules géantes multinucléées à corps étranger sur le site d'implantation. Les inhibiteurs de l'activité GTPasique de la Rho peuvent être fournis séparément du matériau implanté ou, dans un autre mode de réalisation, peuvent être fournis sous la forme d'un composant de la surface externe du matériau implanté. Les procédés de l'invention consistent à mettre en contact des monocytes ou des macrophages avec des inhibiteurs de l'activité GTPasique de la famille des Rho dans des quantités efficaces pour inhiber la fusion desdites cellules, fusion qui débouche sur la création de cellules géantes multinucléées à corps étranger. De préférence, les inhibiteurs de l'activité GTPasique de la Rho sont des inhibiteurs de l'activité GTPasique de la famille des Rac. Dans un mode de réalisation préféré, on utilise un inhibiteur Rac à petites molécules NSC23766.
PCT/US2007/085598 2006-11-27 2007-11-27 Procédés permettant d'inhiber la réaction à corps étranger face à des matériaux implantés Ceased WO2008067288A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86729206P 2006-11-27 2006-11-27
US60/867,292 2006-11-27

Publications (2)

Publication Number Publication Date
WO2008067288A2 WO2008067288A2 (fr) 2008-06-05
WO2008067288A3 true WO2008067288A3 (fr) 2008-08-07

Family

ID=39366994

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/085598 Ceased WO2008067288A2 (fr) 2006-11-27 2007-11-27 Procédés permettant d'inhiber la réaction à corps étranger face à des matériaux implantés

Country Status (1)

Country Link
WO (1) WO2008067288A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130324521A1 (en) * 2010-11-26 2013-12-05 Reza Ghotbi Implant for treating or preventing an aneurysm
WO2022076700A1 (fr) * 2020-10-07 2022-04-14 The Board Of Trustees Of The Leland Stanford Junior University Procédés et compositions de traitement de complications associées à un implant
WO2024049713A1 (fr) * 2022-08-30 2024-03-07 Lintec Of America, Inc. Support de régénération nerveuse améliorée pour une repousse accélérée
EP4630014A1 (fr) 2022-12-09 2025-10-15 CeMM - Forschungszentrum für Molekulare Medizin GmbH Procédé d'optimisation de lymphocytes t pour une immunothérapie

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130722A1 (en) * 2001-12-21 2003-07-10 Marx Steven O. C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
WO2003105923A2 (fr) * 2002-06-14 2003-12-24 The Trustees Of Columbia University In The City Ofnew York Utilisation de y-27632 comme agent destine a prevenir la restenose apres angioplastie d'arteres coronaires/implantation d'endoprothese

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130722A1 (en) * 2001-12-21 2003-07-10 Marx Steven O. C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
WO2003105923A2 (fr) * 2002-06-14 2003-12-24 The Trustees Of Columbia University In The City Ofnew York Utilisation de y-27632 comme agent destine a prevenir la restenose apres angioplastie d'arteres coronaires/implantation d'endoprothese

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOWER T L ET AL: "RhoA is activated during respiratory syncytial virus infection", VIROLOGY, vol. 283, 2001, pages 188 - 196, XP002480818 *
GOWER T L ET AL: "RhoA signalling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphology", JOURNAL OF VIROLOGY, vol. 79, no. 9, May 2005 (2005-05-01), pages 5326 - 5336, XP002480817 *
ORY S ET AL: "Rho and Rac exert antagonistic functions on spreading of macrophage-derived multinucleated cells and are not required for actin fiber formation", JOURNAL OF CELL SCIENCE, vol. 113, 2000, pages 1177 - 1188, XP002480819 *

Also Published As

Publication number Publication date
WO2008067288A2 (fr) 2008-06-05

Similar Documents

Publication Publication Date Title
WO2011049332A3 (fr) Composés thiéno[3,2-d]pyrimidines substitués dans les positions 2 et 7 en tant qu'inhibiteurs de protéine kinase
IL200561A (en) Heterocyclic inhibitors of aspartate protease or their tautomers, their acceptable pharmacy salt, their pharmacy composition and their use
WO2007125310A3 (fr) Combinaisons pharmaceutiques
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
EP2476679A3 (fr) Triazoles substitués utilisés comme inhibiteurs AXL
MX2009004623A (es) Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
EP2303292A4 (fr) Compositions comprenant des cellules souches cardiaques surexprimant des microarn spécifiques et procédés pour les utiliser dans la réparation d'un myocarde lésé
MY144655A (en) Pyrimidine urea derivatives as kinase inhibitors
WO2008057459A3 (fr) Antagonistes de pcsk9
WO2008057458A3 (fr) Antagonistes de pcsk9
WO2008133647A3 (fr) Antagonistes de pcsk9
NO20091548L (no) Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes
WO2009129301A3 (fr) Compositions pharmaceutiques orales dans une dispersion solide moléculaire
EA018193B3 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
EA201100119A1 (ru) Химические соединения 251
MX2009004984A (es) Metodos para conservar la funcion renal utilizando inhibidores de oxidoreductasa de xantina.
WO2011058474A8 (fr) Inhibiteurs de n1-pyrazolospirocétone acétyl-coa carboxylase
EP2484679A3 (fr) Triazoles substitués par n3-hétéroaryle et N5-hétéroaryle triazoles substitués utiles comme inhibiteurs de axl
WO2009009793A3 (fr) Inhibiteurs de akt/pkb à activité antitumorale
WO2008089201A3 (fr) Composés de pipéridine substituée hétérocycliques et leurs utilisations
WO2011047341A3 (fr) Traitement d'idées ou de comportements suicidaires au moyen d'inhibiteurs des récepteurs nicotiniques à l'acétylcholine
MX2010007584A (es) Inhibidores de proteina cinasa y uso de los mismos.
WO2006135604A3 (fr) Inhibiteurs de kinases checkpoint
IL188438A (en) A heterocyclic active drug with five benzoposes, or a pharmaceutically acceptable salt and aster salts product, as well as compounds containing them and their use as @catol - o @ - @ of @ enzyme @ dead G iltransferase @@ comtI

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871580

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07871580

Country of ref document: EP

Kind code of ref document: A2